<p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）股票在周一交易中下跌了 9.2%。该公司股价最低曾达到 33.63 美元，最后交易价为 33.4240 美元。在午盘交易中，共成交了 255,118 股，较平均交易量 210,240 股增加了 21%。该股票此前收盘价为 36.80 美元。</p>
<p>获取 <strong>Rapt Therapeutics</strong> 警报：</p>
<h2>分析师评级变动</h2>
<p>多家股票研究分析师最近对该股票发布了报告。巴克莱将 Rapt Therapeutics 的目标价从 58.00 美元下调至 56.00 美元，并在 11 月 7 日的报告中给予该股票 “增持” 评级。Zacks Research 在 8 月 22 日的报告中将 Rapt Therapeutics 的评级从 “强力买入” 下调至 “持有”。Leerink Partners 在 9 月 26 日的报告中将 Rapt Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该股票的目标价从 16.00 美元上调至 37.00 美元。Leerink Partners 在 9 月 25 日的研究报告中将 Rapt Therapeutics 的评级从 “持有” 上调至 “强力买入”。最后，富国银行在 11 月 3 日的报告中将 Rapt Therapeutics 的目标价设定为 72.00 美元，并给予该公司 “增持” 评级。两位分析师给予该股票 “强力买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 50.50 美元。</p>
<p><strong>阅读我们关于 Rapt Therapeutics 的最新股票报告</strong></p>
<h2>Rapt Therapeutics 股票下跌 9.7%</h2>
<p>该股票的 50 日简单移动平均线为 30.39 美元，200 日简单移动平均线为 18.69 美元。该公司的市值为 9.2053 亿美元，市盈率为-3.00，贝塔值为 0.43。</p>
<p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）最近在 11 月 6 日公布了其财报。该公司报告本季度每股收益为（0.65 美元），超出市场共识预期的（0.88 美元）0.23 美元。研究分析师平均预测 Rapt Therapeutics 在当前财政年度的每股收益为-2.14 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近买入和卖出了该股票的股份。Invesco Ltd.在第一季度将其在 Rapt Therapeutics 的持股增加了 411.7%。Invesco Ltd.目前拥有 58,901 股该公司的股票，价值 72,000 美元，此前在该期间内又购买了 47,391 股。Comerica Bank 在第一季度将其在 Rapt Therapeutics 的持股增加了 53.9%。Comerica Bank 目前拥有 89,327 股该公司的股票，价值 109,000 美元，此前又购买了 31,287 股。Checkpoint Capital L.P.在第一季度购买了 Rapt Therapeutics 的新股份，价值约为 134,000 美元。Nuveen LLC 在第一季度购买了 Rapt Therapeutics 的新股份，价值约为 143,000 美元。最后，查尔斯·施瓦布投资管理公司在第一季度将其在 Rapt Therapeutics 的持股增加了 112.7%。查尔斯·施瓦布投资管理公司目前拥有 150,946 股该公司的股票，价值 184,000 美元，此前又购买了 79,967 股。99.09% 的股票由机构投资者持有。</p>
<h2>关于 Rapt Therapeutics</h2>
<p>（获取免费报告）</p>
<p>RAPT Therapeutics, Inc.是一家临床阶段的基于免疫学的生物制药公司，专注于发现、开发和商业化针对美国肿瘤和炎症疾病患者未满足需求的口服小分子疗法。该公司的主要炎症药物候选者是 zelnecirnon（RPT193），这是一种 C-C 基序趋化因子受体 4（CCR4）拮抗剂，能够选择性抑制 2 型 T 辅助细胞向炎症组织的迁移。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Rapt Therapeutics</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>Nutanix 是 2025 年最佳反弹交易吗？设置表明是</li>
<li>如何交易便士股票：逐步指南</li>
<li>Vertiv 回调：忽略噪音，购买数据</li>
<li>如何捕捉股息增加的好处</li>
<li>内部人士购买天然气股票：2 只在观察名单上</li>
</ul>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Rapt Therapeutics 吗？</h2>
<p>在你考虑 Rapt Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Rapt Therapeutics 并不在名单上。</p>
<p>虽然 Rapt Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RAPT

<p>Rapt Therapeutics（纳斯达克代码：RAPT）周一股价下跌 9.2%，最低交易价为 33.63 美元。尽管股价下跌，分析师的评级却不尽相同：巴克莱设定目标价为 56 美元，扎克斯下调至 “持有”，而 Leerink Partners 则上调至 “跑赢大盘”，目标价为 37 美元。该股票的共识评级为 “适度买入”，目标价为 50.50 美元。机构投资者持有 99.09% 的股份。Rapt 专注于开发肿瘤和炎症疾病的治疗方案</p>

<p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) shares traded down 9.2% during trading on Monday . The company traded as low as $33.63 and last traded at $33.4240. 255,118 shares changed hands during mid-day trading, an increase of 21% from the average session volume of 210,240 shares. The stock had previously closed at $36.80.</p>
<div class="lb-trans"><p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）股票在周一交易中下跌了 9.2%。该公司股价最低曾达到 33.63 美元，最后交易价为 33.4240 美元。在午盘交易中，共成交了 255,118 股，较平均交易量 210,240 股增加了 21%。该股票此前收盘价为 36.80 美元。</p>
</div><p>Get <strong>Rapt Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rapt Therapeutics</strong> 警报：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities research analysts have recently issued reports on the stock. Barclays dropped their target price on shares of Rapt Therapeutics from $58.00 to $56.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, November 7th. Zacks Research lowered Rapt Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, August 22nd. Leerink Partners raised shares of Rapt Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and raised their target price for the stock from $16.00 to $37.00 in a report on Friday, September 26th. Leerink Partnrs raised Rapt Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, September 25th. Finally, Wells Fargo &amp; Company set a $72.00 target price on Rapt Therapeutics and gave the company an &#34;overweight&#34; rating in a report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $50.50.</p>
<div class="lb-trans"><p>多家股票研究分析师最近对该股票发布了报告。巴克莱将 Rapt Therapeutics 的目标价从 58.00 美元下调至 56.00 美元，并在 11 月 7 日的报告中给予该股票 “增持” 评级。Zacks Research 在 8 月 22 日的报告中将 Rapt Therapeutics 的评级从 “强力买入” 下调至 “持有”。Leerink Partners 在 9 月 26 日的报告中将 Rapt Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并将该股票的目标价从 16.00 美元上调至 37.00 美元。Leerink Partners 在 9 月 25 日的研究报告中将 Rapt Therapeutics 的评级从 “持有” 上调至 “强力买入”。最后，富国银行在 11 月 3 日的报告中将 Rapt Therapeutics 的目标价设定为 72.00 美元，并给予该公司 “增持” 评级。两位分析师给予该股票 “强力买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 50.50 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Rapt Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Rapt Therapeutics 的最新股票报告</strong></p>
</div><h2>Rapt Therapeutics Stock Down 9.7%</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 股票下跌 9.7%</h2>
</div><p>The stock's 50-day simple moving average is $30.39 and its 200 day simple moving average is $18.69. The firm has a market cap of $920.53 million, a P/E ratio of -3.00 and a beta of 0.43.</p>
<div class="lb-trans"><p>该股票的 50 日简单移动平均线为 30.39 美元，200 日简单移动平均线为 18.69 美元。该公司的市值为 9.2053 亿美元，市盈率为-3.00，贝塔值为 0.43。</p>
</div><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.23. On average, research analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Rapt Therapeutics（纳斯达克代码：RAPT - 获取免费报告）最近在 11 月 6 日公布了其财报。该公司报告本季度每股收益为（0.65 美元），超出市场共识预期的（0.88 美元）0.23 美元。研究分析师平均预测 Rapt Therapeutics 在当前财政年度的每股收益为-2.14 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its holdings in shares of Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company's stock valued at $72,000 after purchasing an additional 47,391 shares during the period. Comerica Bank grew its stake in shares of Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares during the period. Checkpoint Capital L.P. bought a new stake in Rapt Therapeutics in the 1st quarter valued at about $134,000. Nuveen LLC bought a new stake in Rapt Therapeutics in the 1st quarter valued at about $143,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Rapt Therapeutics by 112.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company's stock worth $184,000 after buying an additional 79,967 shares during the period. 99.09% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了该股票的股份。Invesco Ltd.在第一季度将其在 Rapt Therapeutics 的持股增加了 411.7%。Invesco Ltd.目前拥有 58,901 股该公司的股票，价值 72,000 美元，此前在该期间内又购买了 47,391 股。Comerica Bank 在第一季度将其在 Rapt Therapeutics 的持股增加了 53.9%。Comerica Bank 目前拥有 89,327 股该公司的股票，价值 109,000 美元，此前又购买了 31,287 股。Checkpoint Capital L.P.在第一季度购买了 Rapt Therapeutics 的新股份，价值约为 134,000 美元。Nuveen LLC 在第一季度购买了 Rapt Therapeutics 的新股份，价值约为 143,000 美元。最后，查尔斯·施瓦布投资管理公司在第一季度将其在 Rapt Therapeutics 的持股增加了 112.7%。查尔斯·施瓦布投资管理公司目前拥有 150,946 股该公司的股票，价值 184,000 美元，此前又购买了 79,967 股。99.09% 的股票由机构投资者持有。</p>
</div><h2>About Rapt Therapeutics</h2>
<div class="lb-trans"><h2>关于 Rapt Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.</p>
<div class="lb-trans"><p>RAPT Therapeutics, Inc.是一家临床阶段的基于免疫学的生物制药公司，专注于发现、开发和商业化针对美国肿瘤和炎症疾病患者未满足需求的口服小分子疗法。该公司的主要炎症药物候选者是 zelnecirnon（RPT193），这是一种 C-C 基序趋化因子受体 4（CCR4）拮抗剂，能够选择性抑制 2 型 T 辅助细胞向炎症组织的迁移。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Rapt Therapeutics</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Is Nutanix the Best Comeback Trade Left in 2025? The Setup Says Yes</li>
<li>How to trade penny stocks: A step-by-step guide</li>
<li>The Vertiv Pullback: Ignore the Noise, Buy the Data</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Insiders Buy Natural Gas Stocks: 2 for the Watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Rapt Therapeutics</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>Nutanix 是 2025 年最佳反弹交易吗？设置表明是</li>
<li>如何交易便士股票：逐步指南</li>
<li>Vertiv 回调：忽略噪音，购买数据</li>
<li>如何捕捉股息增加的好处</li>
<li>内部人士购买天然气股票：2 只在观察名单上</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rapt Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rapt Therapeutics 吗？</h2>
</div><p>Before you consider Rapt Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Rapt Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Rapt Therapeutics 并不在名单上。</p>
</div><p>While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rapt Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

RAPT Therapeutics（纳斯达克代码：RAPT）股价下跌 9.2% - 你是否应该卖出？